Compared side by side
MOTS-c vs SLU-PP-332: how they differ
The short answer
Both are called exercise mimetics, from different starting points: MOTS-c is a peptide encoded by mitochondrial DNA that activates AMPK in mice, and SLU-PP-332 is a small molecule (not a peptide) that switches on the ERR receptors behind mitochondria and endurance in muscle. In mice, MOTS-c improved insulin sensitivity and exercise capacity, and SLU-PP-332 lengthened treadmill runs by about 70%. Neither has been tested in people; MOTS-c is injected 2–3 times a week, and SLU-PP-332 is sold as a daily capsule, though its developers report it lacks oral bioavailability.
Side by side
| Compared | MOTS-c | SLU-PP-332 |
|---|---|---|
| Category | Longevity | Metabolic & GLP-1 |
| Also known as | Mitochondrial Open Reading Frame of the 12S rRNA-c | SLU PP 332, SLUPP332, SLU-PP332 |
| What it is | A peptide encoded by your mitochondrial DNA, the energy-producing organelles inside every cell. | An experimental "exercise mimetic": a small molecule (not a peptide) from a St. |
| How it works | Mitochondria-derived peptide that regulates metabolic homeostasis. In mouse and cell studies it activates the AMPK pathway, improves insulin sensitivity and exercise capacity, and slows some signs of aging. | Synthetic small molecule (not a peptide) that switches on the estrogen-related receptors ERRα, ERRβ and ERRγ, most strongly ERRα. These receptors run the genes behind mitochondria, fat burning and endurance in muscle, so in mice it mimics parts of aerobic training: more oxidative muscle fibers, more energy expenditure and longer treadmill runs. Despite the name, ERRs don't bind estrogen. All of its research is in mice and cells; it has never been given to people in a study, and its own developers report that it lacks oral bioavailability. |
| Commonly reported | More energy and better workout endurance over the first weeks, sometimes after a week or two of feeling tired. No human trial has tested it yet. | Some users describe cardio feeling easier, without getting as gassed; others notice nothing. |
| Studied range | Research range: 5–10 mg. Studied in research — not a recommendation. | Research range: 250–1000 mcg, starting dose 250 mcg. Studied in research — not a recommendation. |
| How often | 2–3× weekly | Daily |
| Half-life | Hours (short) | Unknown: never measured in people; in mice, levels in muscle were about three times those in blood 2 hours after an injection |
| Route | SubQ injection, IM injection | Oral capsule |
| Typical run | 4–8 week cycles common, 2–3× per year. Common splits: Mon/Thu (2× weekly) or Mon/Wed/Fri (3× weekly). Limited long-term human data — none on continuous dosing. | Community runs commonly last about 8 weeks with about 4 weeks off; no study has tested any schedule in people. |
| Evidence | Emerging: primarily preclinical / limited human data | Emerging: primarily preclinical / limited human data |
| Common side effects | Injection site reaction, mild fatigue first week | No human safety data, unknown long-term effects |
- Category
- MOTS-cLongevity
- SLU-PP-332Metabolic & GLP-1
- Also known as
- MOTS-cMitochondrial Open Reading Frame of the 12S rRNA-c
- SLU-PP-332SLU PP 332, SLUPP332, SLU-PP332
- What it is
- MOTS-cA peptide encoded by your mitochondrial DNA, the energy-producing organelles inside every cell.
- SLU-PP-332An experimental "exercise mimetic": a small molecule (not a peptide) from a St.
- How it works
- MOTS-cMitochondria-derived peptide that regulates metabolic homeostasis. In mouse and cell studies it activates the AMPK pathway, improves insulin sensitivity and exercise capacity, and slows some signs of aging.
- SLU-PP-332Synthetic small molecule (not a peptide) that switches on the estrogen-related receptors ERRα, ERRβ and ERRγ, most strongly ERRα. These receptors run the genes behind mitochondria, fat burning and endurance in muscle, so in mice it mimics parts of aerobic training: more oxidative muscle fibers, more energy expenditure and longer treadmill runs. Despite the name, ERRs don't bind estrogen. All of its research is in mice and cells; it has never been given to people in a study, and its own developers report that it lacks oral bioavailability.
- Commonly reported
- MOTS-cMore energy and better workout endurance over the first weeks, sometimes after a week or two of feeling tired. No human trial has tested it yet.
- SLU-PP-332Some users describe cardio feeling easier, without getting as gassed; others notice nothing.
- Studied range
- MOTS-cResearch range: 5–10 mg. Studied in research — not a recommendation.
- SLU-PP-332Research range: 250–1000 mcg, starting dose 250 mcg. Studied in research — not a recommendation.
- How often
- MOTS-c2–3× weekly
- SLU-PP-332Daily
- Half-life
- MOTS-cHours (short)
- SLU-PP-332Unknown: never measured in people; in mice, levels in muscle were about three times those in blood 2 hours after an injection
- Route
- MOTS-cSubQ injection, IM injection
- SLU-PP-332Oral capsule
- Typical run
- MOTS-c4–8 week cycles common, 2–3× per year. Common splits: Mon/Thu (2× weekly) or Mon/Wed/Fri (3× weekly). Limited long-term human data — none on continuous dosing.
- SLU-PP-332Community runs commonly last about 8 weeks with about 4 weeks off; no study has tested any schedule in people.
- Evidence
- MOTS-cEmerging: primarily preclinical / limited human data
- SLU-PP-332Emerging: primarily preclinical / limited human data
- Common side effects
- MOTS-cInjection site reaction, mild fatigue first week
- SLU-PP-332No human safety data, unknown long-term effects
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Model. Individual results vary.
Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
MOTS-c
- Day 1–14 The first two weeks
- Day 14–28 Workouts often feel easier
- Day 28–56 Weeks 4 to 8: check your markers
- Day 56–84 Diminishing returns + cycle point
SLU-PP-332
- Day 1–14 Week one: an honest baseline
- Day 15–56 How it burns fat
- Day 57–84 Weeks 8 to 12: where community runs pause
Together or one or the other
MOTS-c and SLU-PP-332 are a common stack: SLU-PP-332 lists MOTS-c among its common stacks.
Community · SLU-PP-332
Why people pair it with MOTS-c and SS-31
A common community stack aims at mitochondria from three sides: SLU-PP-332 at the ERR receptors, MOTS-c at the AMPK exercise pathway, SS-31 at the inner mitochondrial membrane. With three compounds started together, there is no telling which one did what. Commonly reported: better endurance, credited to the stack as a whole.
Questions people ask
How long do MOTS-c and SLU-PP-332 last?
The half-life of MOTS-c is hours (short). The half-life of SLU-PP-332 is unknown: never measured in people; in mice, levels in muscle were about three times those in blood 2 hours after an injection.
How often are MOTS-c and SLU-PP-332 taken?
MOTS-c: 2–3× weekly. Routes: SubQ injection, IM injection. SLU-PP-332: daily. Route: Oral capsule.
How are MOTS-c and SLU-PP-332 dosed in research?
The research range for MOTS-c is 5–10 mg. The research range for SLU-PP-332 is 250–1000 mcg, with a 250 mcg starting dose. Studied in research — not a recommendation.
What are the common side effects of MOTS-c and SLU-PP-332?
For MOTS-c, the library lists: injection site reaction, mild fatigue first week. For SLU-PP-332: no human safety data, unknown long-term effects.
Are MOTS-c and SLU-PP-332 taken together?
MOTS-c and SLU-PP-332 are a common stack: SLU-PP-332 lists MOTS-c among its common stacks. A common community stack aims at mitochondria from three sides: SLU-PP-332 at the ERR receptors, MOTS-c at the AMPK exercise pathway, SS-31 at the inner mitochondrial membrane. With three compounds started together, there is no telling which one did what. Commonly reported: better endurance, credited to the stack as a whole.